• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Samsung Biologics IPO could reach $2B, company value above $8B

Samsung Biologics IPO could reach $2B, company value above $8B

October 4, 2016 By Fink Densford

Samsung BiologicsBiotech drug contract manufacturer Samsung BioLogics could pull in as much as $2 billion through an initial public offering, according to regulatory filings posted this week.  The figures would position it as South Korea’s 3rd-largest IPO.

BioLogics, which is 47.8% owned by Samsung Electronics (LON:BC94), this week gave new information on the planned offering, which would value the company at up to $8.2 billion as it seeks regulatory clearance for a new cancer treatment.

Samsung BioLogics said it will offer 16.5 million shares priced between $102.50 and $123.17, setting the IPO up to bring in between $1.7 and $2 billion.

The offering of 25% of the company is expected to consist of a new share issue of 11 million shares and the sale of 5.5 million existing shares by Samsung Electronics.

Money raised in the offering will support funding an expansion of production capacity that could make Samsung BioLogics the world’s largest contract manufacturer of biotech medicines.

The offering will also help funnel resources to its unlisted unit Samsung Bioepis, which aims to beat rivals to market with its lower-cost copies of some of the world’s top-selling biotech drugs called biosimilars.

Material from Reuters was used in this report.

Filed Under: Business/Financial News Tagged With: Samsung Bioepis Co Ltd, Samsung BioLogics, Samsung Electronics Co. Ltd.

More recent news

  • Presidio wins FDA IDE for ultra-low frequency neuromod, hires new CFO
  • Epiminder study backs implantable EEG tech
  • Neurent Medical wins FDA nod for next-gen chronic rhinitis treatment
  • Medtronic unveils “MiniMed” as name for soon-to-be separated Diabetes unit
  • Medtronic issues safety notice for Hugo surgical robot console in Europe

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy